CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 141 enrolled
Drug / intervention
Ondansetron 4 MG +1 moredrug
Likely dose
Ondansetron 4 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03297021
NCT03297021Phase 4Completed
CompareCT.gov

Effects of Ondansetron Dose and Timing on Rates of Post-operative Nausea and Vomiting

Icahn School of Medicine at Mount Sinai·interventional·Posted Sep 29, 2017·Updated Jul 20, 2020

In Brief

A Phase 4 clinical trial evaluating Ondansetron 4 MG and Ondansetron 8mg for Post-operative Nausea and Vomiting. Completed, enrolled 141 participants across 1 site.

Detailed Summary

The aim is to evaluate the effectiveness of three different regimens of prophylactic ondansetron on the incidence and severity of post-operative nausea and vomiting.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost-operative Nausea and Vomiting
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedSep 29, 2017
Enrollment StartOct 23, 2017
Primary CompletionApr 5, 2019
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 8.8 years ago

Interventions

Ondansetron 4 MGdrug

dose as per arm selection

Ondansetron 8mgdrug

dose as per arm selection